These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

995 related articles for article (PubMed ID: 32102694)

  • 1. Large-scale public data reuse to model immunotherapy response and resistance.
    Fu J; Li K; Zhang W; Wan C; Zhang J; Jiang P; Liu XS
    Genome Med; 2020 Feb; 12(1):21. PubMed ID: 32102694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma.
    Yang J; Zhao S; Wang J; Sheng Q; Liu Q; Shyr Y
    J Genet Genomics; 2021 May; 48(5):361-368. PubMed ID: 34127402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response.
    Zeng Z; Wong CJ; Yang L; Ouardaoui N; Li D; Zhang W; Gu S; Zhang Y; Liu Y; Wang X; Fu J; Zhou L; Zhang B; Kim S; Yates KB; Brown M; Freeman GJ; Uppaluri R; Manguso R; Liu XS
    Nucleic Acids Res; 2022 Jan; 50(D1):D1391-D1397. PubMed ID: 34534350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy.
    Crow J; Samuel G; Godwin AK
    Expert Rev Mol Diagn; 2019 Dec; 19(12):1079-1088. PubMed ID: 31687863
    [No Abstract]   [Full Text] [Related]  

  • 6. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.
    Jia Q; Wang J; He N; He J; Zhu B
    JCI Insight; 2019 May; 4(10):. PubMed ID: 31092729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the impact of age on immune checkpoint therapy biomarkers.
    Erbe R; Wang Z; Wu S; Xiu J; Zaidi N; La J; Tuck D; Fillmore N; Giraldo NA; Topper M; Baylin S; Lippman M; Isaacs C; Basho R; Serebriiskii I; Lenz HJ; Astsaturov I; Marshall J; Taverna J; Lee J; Jaffee EM; Roussos Torres ET; Weeraratna A; Easwaran H; Fertig EJ
    Cell Rep; 2021 Aug; 36(8):109599. PubMed ID: 34433020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIRSF: a web server for screening gene signatures to predict Tumor immunotherapy response.
    Chen L; Chen T; Zhang Y; Lin H; Wang R; Wang Y; Li H; Zuo Z; Ren J; Xie Y
    Nucleic Acids Res; 2022 Jul; 50(W1):W761-W767. PubMed ID: 35554556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR screen in mechanism and target discovery for cancer immunotherapy.
    Liu D; Zhao X; Tang A; Xu X; Liu S; Zha L; Ma W; Zheng J; Shi M
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188378. PubMed ID: 32413572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
    Nishino M; Ramaiya NH; Hatabu H; Hodi FS
    Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic basis for response to cancer immunotherapy.
    Gruber K
    Lancet Oncol; 2017 Sep; 18(9):e521. PubMed ID: 28826592
    [No Abstract]   [Full Text] [Related]  

  • 12. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of Immune Oncology: Challenges and Opportunities.
    Cesano A; Marincola FM; Thurin M
    Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IV. Development and Future Perspective of Immune Checkpoint Blockade Therapy].
    Tamada K
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):661-665. PubMed ID: 28860437
    [No Abstract]   [Full Text] [Related]  

  • 15. ICBcomb: a comprehensive expression database for immune checkpoint blockade combination therapy.
    Xia Y; Gao Y; Liu MY; Li L; Pan W; Mao LZ; Yang Z; Yang M; Guo AY
    Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38095856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
    Xiang Z; Yu Y
    Front Med; 2019 Feb; 13(1):24-31. PubMed ID: 30659409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma.
    Wang J; Li F; Xu Y; Zheng X; Zhang C; Hu C; Xu Y; Mi W; Li X; Zhang Y
    J Transl Med; 2021 Jul; 19(1):296. PubMed ID: 34238310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
    Xiao Q; Nobre A; Piñeiro P; Berciano-Guerrero MÁ; Alba E; Cobo M; Lauschke VM; Barragán I
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31968651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for Immunotherapy: Current Developments and Challenges.
    Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplatform Integrative Analysis of Immunogenomic Data for Biomarker Discovery.
    Thorsson V
    Methods Mol Biol; 2020; 2055():679-698. PubMed ID: 31502174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.